Tweet

Martin Landray

15 Oct, 4 tweets, 1 min read

@WHO

The @WHO SOLIDARITY trial is a major international achievement.

Knowing which treatments do not have meaningful impact on mortality is important - saves resources, refocuses scientific attention, benefits patients.

https://twitter.com/FinancialTimes/status/1316822064427339776

Doubtless there will be much discussion, not all of which will be as objective as we need in a pandemic.

But this trial is randomised, large, and focused on the ultimate clinical outcome - mortality.

Huge congratulations to all involved - from top to bottom, from around the world.

And here is the pre-print:

medrxiv.org/content/10.110…

• • •

Missing some Tweet in this thread? You can try to force a refresh

This Thread may be Removed Anytime!

Twitter may remove this content at anytime! Save it as PDF for later use!

More from @MartinLandray

Martin Landray

@MartinLandray

16 Oct

@WHO

Results of the @WHO SOLIDARITY trial:

4 drugs tested in 11,266 patients with COVID in 405 hospitals in 30 countries:
- hydroxychloroquine
- lopinavir
- remdesevir
- interferon

No clear benefit of any of them on survival.

medrxiv.org/content/10.110…

Similar results in different age-groups and whether on mechanical ventilation or not:

We knew about hydroxychloroquine - these results are entirely consistent with RECOVERY:

nejm.org/doi/full/10.10…

Read 10 tweets

Martin Landray

@MartinLandray

8 Oct

More results from the RECOVERY trial - Hydroxychloroquine:

Among patients hospitalised with COVID-19, hydroxychloroquine (HCQ) did not improve 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death

nejm.org/doi/full/10.10…

1561 patients were randomised to HCQ + usual care
3155 patients were randomised to usual care alone
in the largest randomised trial of HCQ for treatment of COVID

No evidence of benefit of HCQ on any of the pre-specified endpoints.

Read 14 tweets

Martin Landray

@MartinLandray

7 Oct

@rupert_pearse

Great summary of treatments for hospitalised patients with COVID-19 @rupert_pearse

threadreaderapp.com/thread/1312699…

My take on this:

Dexamethasone improves survival.
Remdesivir shortens time to recovery.
Hydroxychloroquine & lopinavir are ineffective.

** we know because the clinical trials have been done**

Tocilizumab, Convalescent plasma, and neutralising antibodies look promising

** we will know because we are doing the clinical trials**

Read 5 tweets

Martin Landray

@MartinLandray

6 Oct

Latest paper from RECOVERY trial:

In patients admitted to hospital with COVID-19, lopinavir–ritonavir did not reduce 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death.

thelancet.com/journals/lance…

Lopinavir-ritonavir is an HIV treatment that was widely recommended and used for #COVID19. The RECOVERY trial has shown it does not work - so doctors no longer use it.

That’s why we do trials - to separate out drugs we think might work from drugs we know do work.

@UKRI_News

As always, huge thanks to all involved including funders (@UKRI_News @NIHRresearch), colleagues (@OxfordBRC @hdruk @Oxford_NDPH @NDMOxford), the NHS (@NHSEngland @NHSDigital) and the thousands of medical staff across the whole UK.

But most especially to our amazing patients.

Read 9 tweets